BRPI0507302A - método e composições para o tratamento da lipodistrofia - Google Patents

método e composições para o tratamento da lipodistrofia

Info

Publication number
BRPI0507302A
BRPI0507302A BRPI0507302-2A BRPI0507302A BRPI0507302A BR PI0507302 A BRPI0507302 A BR PI0507302A BR PI0507302 A BRPI0507302 A BR PI0507302A BR PI0507302 A BRPI0507302 A BR PI0507302A
Authority
BR
Brazil
Prior art keywords
lipodystrophy
treatment
compositions
methods
hiv patients
Prior art date
Application number
BRPI0507302-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Giampiero De Luca
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of BRPI0507302A publication Critical patent/BRPI0507302A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0507302-2A 2004-01-29 2005-01-26 método e composições para o tratamento da lipodistrofia BRPI0507302A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54020404P 2004-01-29 2004-01-29
US54336604P 2004-02-10 2004-02-10
PCT/EP2005/000758 WO2005074916A1 (en) 2004-01-29 2005-01-26 Methods and compositions for the treatment of lipodystrophy

Publications (1)

Publication Number Publication Date
BRPI0507302A true BRPI0507302A (pt) 2007-06-26

Family

ID=34841102

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507302-2A BRPI0507302A (pt) 2004-01-29 2005-01-26 método e composições para o tratamento da lipodistrofia

Country Status (10)

Country Link
EP (1) EP1722778A1 (ko)
JP (1) JP2007519669A (ko)
KR (1) KR20060127977A (ko)
AU (1) AU2005210093A1 (ko)
BR (1) BRPI0507302A (ko)
CA (1) CA2552404A1 (ko)
EA (1) EA200601392A1 (ko)
IL (1) IL176762A0 (ko)
NO (1) NO20063279L (ko)
WO (1) WO2005074916A1 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
AU2008353145B2 (en) * 2008-01-03 2013-09-12 Universite D' Aix-Marseille Bitherapy and tritherapy used for treating an HIV-positive patient
EP2421548A4 (en) * 2009-04-20 2012-09-26 Theratechnologies Inc USE OF (HEXENOYL-TRANS-3) HGRF (L-44) NH2 AND SIMVASTATIN IN COMBINATION THERAPY
WO2015138278A1 (en) * 2014-03-11 2015-09-17 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9803623D0 (sv) * 1998-10-22 1998-10-22 Sahltech Ab New therapeutic application

Also Published As

Publication number Publication date
JP2007519669A (ja) 2007-07-19
EP1722778A1 (en) 2006-11-22
IL176762A0 (en) 2006-10-31
NO20063279L (no) 2006-09-19
AU2005210093A1 (en) 2005-08-18
KR20060127977A (ko) 2006-12-13
EA200601392A1 (ru) 2006-12-29
CA2552404A1 (en) 2005-08-18
WO2005074916A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
CY1125077T1 (el) Αγωγη της ανεπαρκειας και ελλειψης βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3
NZ593474A (en) Compositions and methods for treatment of celiac disease
MX2010006519A (es) Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina.
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
ECSP074704A (es) Combinaciones de inhibidor(es) de la absorción de esterol con modificador(es) sanguíneos para tratar cuadros vasculares
EA201301078A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
MX2010002498A (es) Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol.
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
TW200716224A (en) Method of indentifying therapeutic targets for the treatment of vulvovaginal atrophy
EA201290356A1 (ru) Композиции для лечения тошноты и рвоты центрального происхождения
SG10201407403UA (en) Treatments For Gastrointestinal Disorders
DK1505990T3 (da) Fremgangsmåder til behandling af hepatitis
MX2009005114A (es) Uso de los profarmacos gabapentina y pregabalina para tratar el tinnitus.
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
BR112012006468A2 (pt) métodos de tratamento de inflamação
EA201001749A1 (ru) Способ лечения недифференцированного артрита
NO20072167L (no) Kombinasjon omfattende ZD6474 og et antiandrogen
BR112013022217A2 (pt) composição farmacêutica, método de tratamento preventivo de uma síndroma hemorrágica em um paciente com hemofilia a ou b e método de tratamento de um acidente hemorrágico em um paciente com hemofilia a ou b
EA201200428A1 (ru) Композиция и способ для лечения ожирения
BR112013007423A2 (pt) terapia combinada no que diz respeito ao tratamento da infecção por hcv
ATE468849T1 (de) Idebenon zur behandlung von muskeldystrophien

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LABORATOIRES SERONO S.A. (CH)

Free format text: TRANSFERIDO DE: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.